Triple-Drug KRAS Attack Erases Pancreatic Tumors in Mice
TL;DR
CNIO researchers report a triple-drug regimen that blocks the KRAS signaling pathway at three points—using daraxonrasib, afatinib, and SD36—to induce durable tumor regression and prevent resistance in three mouse models of pancreatic ductal adenocarcinoma (PDAC) with minimal toxicity. While promising, they caution that the approach is not yet ready for clinical trials and would require further development to adapt for human use, per the PNAS study.
- New Pancreatic Cancer Treatment Wipes Out Tumors and Blocks Drug Resistance SciTechDaily
- New strategy intercepts pancreatic cancer by eliminating microscopic lesions before they become cancer Medical Xpress
- Combined CDK4/6 and EGFR inhibition improves pancreatic cancer therapy News-Medical
- Routine Screening Catches Couple’s Cancers Early Cedars-Sinai
- KRAS Inhibitors Intercept Pancreatic Cancer Before It Develops in Mice Inside Precision Medicine
Want the full story? Read the original reporting
Read on SciTechDaily